Update on Pharmasset's Hepatitis C Drug Candidates

[Guest guest]

Update on Pharmasset's Hepatitis C Drug Candidates

Pharmasset has released interim study results for several of its Hepatitis C drugs that are in different stages of testing.

Pharmasset Reports Interim Study Results For Its Hepatitis C Drugs

Thursday, January 06, 2011

Pharmasset (NASDAQ:VRUS) announced today interim results for the Phase 2b study for its PSI-7977 drug and the Phase 1 study for its PSI-938 drug. Both drugs are designed to treat Hepatitis C.

The Phase 2b study consisted of evaluating the effects of various PSI-7977 dosages in patients with Hepatitis C genotype 1, 2 or 3. The patients also received antiviral drugs commonly used to fight Hepatitis C.

Continue reading this entire article:http://www.proactiveinvestors.com/companies/news/11228/pharmasset-reports-interim-study-results-for-its-hepatitis-c-drugs--11228.html

http://www.hepatitis-central.com/mt/archives/2011/01/update_on_pharm.html